Skip to main content
SpringerLink
Log in

Einführende Daten über Cephacetril

Introductory remarks on cephacetrile

  • Experimentelle Und Klinische Grundlagen
  • Published:
Infection Aims and scope Submit manuscript

Zusammenfassung

Es wird eine Übersicht gegeben über die internationalen Erfahrungen mit Cephacetril hinsichtlich Bakteriologie, Pharmakologie und Klinik. Cephacetril hat dasselbe antibakterielle Wirkungsspektrum wie die anderen eingeführten Cephalosporine. Im Gegensatz zu einigen dieser Präparate besitzt Cephacetril eine recht gute Stabilität gengenüber einigen β-Lactamasen. Cephacetril weist eine geringe Eiweißbindung auf und bietet einen hohen Anteil von freiem Wirkstoff für Verteilung und antibakteriellen Effekt. Das apparente Verteilungsvolumen ist hoch im Vergleich zu den meisten anderen Cephalosporinen. Die Verträglichkeit, insbesondere die Nierenverträglichkeit des Präparates, ist gut, was u. a. in der Höhe der maximalen Tagesdosis zum Ausdruck kommt sowie im Fehlen von klinischen Berichten über Nephrotoxizität. Cephacetril kann sowohl intravenös als auch intramuskulär verabreicht werden. Die Indikationen für Cephacetril sind dieselben wie für die übrigen eingeführten Cephalosporine, jedoch besitzt Cephacetril als zusätzliche Indikation die bakterielle Meningitis, verursacht durch empfindliche Erreger, bei der es eine hohe therapeutische Erfolgsquote aufweist.

Summary

The paper contains a review of the international experience obtained with cephacetrile as regards the bacteriological, pharmacological and clinical characteristics of the drug. Cephacetrile has the same spectrum of antibacterial action as the other introduced cephalosporins. Unlike some of the latter, cephacetrile is markedly stable with respect to various β-lactamases. Cephacetrile demonstrates low protein binding, which means that a large portion of the drug is distributed in free form and thus has a direct antibacterial effect. The distribution volume is high in comparison with that of most other cephalosporins. The tolerability of the drug, including in particular its renal tolerability, is good, as is evident from the size of the maximum permissible daily dose and the absence of any clinical reports on nephrotoxicity. Cephacetrile can be given both i. v. and i. m. The indications for cephacetrile are the same as those for other cephalosporins, with the exception that it can also be used to very good effect in cases of bacterial meningitis provided the pathogens are sensitive to the drug.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Brogard, J. M., Pinget, M., Dorner, M., Lavillaureix, J. General characteristics of cephalosporin derivatives. Comparative pharmacology. Int. Symp. on Future Trends in Chemotherapy, Pisa 1974. Medicament. Actualid. 10 (1974) Suppl. 21–32.

    Google Scholar 

  2. Dettli, L., Spring, P., Ryter, S. Multiple dose kinetics and drug dosage in patients with kidney disease. Acta pharmacol. 29 (1971) Suppl. 3, 211–224.

    Google Scholar 

  3. Dettli, L., Spring, P., Reber, H.: The elimination of a new cephalosporin analogue in patients with normal and with impaired kidney function abstracts. 7th Int. Congr. of Chemotherapy. Prague 1971, Vol. 1.

  4. Di Nola, F., Soranzo, M. L. Comparative trial of cephacetrile versus cephaloridine in the treatment of secondary respiratory infections in childhood pertussis. Arzneimittel-Forsch. 24 (1974) 1510–1512.

    Google Scholar 

  5. Duval, J., Mora, M., Soussy, C. J. Pharmacocinétique d'une nouvelle céphalosporine, la céphacétrile. Taux sériques et urinaires chez l'adult et le prématuré. Diffusion méningée et passage transplacentaire. Méd. Mal. Infect. 4 (1974) 221–229.

    Google Scholar 

  6. Eckolt, R., Bürgi, H., Regli, J. Comparative trial of ampicillin and CIBA 36'278-Ba in acute exacerbations of chronic bronchitis. Advances in Antimicrobial and Antineoplastic Chemotherapy. Proc. 7th Int. Conr. of Chemotherapy, Prague 1971, S. 1245–1246. Urban & Schwarzenberg, München 1972.

    Google Scholar 

  7. Fare, L. R., Actor, P., Sachs, C., Phillips, L., Ioloza, M., Pauls, J. F., Weisbach, J. A. Comparative serum levels and protective activity of parenterally administered cephalosporins in experimental animals. Antimicrob. Agents Chemother. 6 (1974) 150–155.

    PubMed  Google Scholar 

  8. Fee, W. H., Winter, M. D., Bright, T. P., Smith, J. W., Farber, M. O., Bartram, C. E. Cephacetrile in the treatment of acute bacterial pneumonia. Curr. ther. Res. 17 (1975) 419–426.

    PubMed  Google Scholar 

  9. Jackson, G. G. Practice, precision, and promise in chemotherapy. Proc. 8th Int. Congr. Chemother., Athens 1973. (Ed.:G. K. Daikos), Vol. 1, Antibacterial chemotherapy, S. 3–10. Hellenic society for Chemotherapy, Athens 1974.

    Google Scholar 

  10. Kradolfer, F., Ahrens, T., Gelzer, J., Vischer, W., Zimmermann, W. Experimentelle Evaluierung des neuen Cephalosporin-Antibiotikums Celospor (Cephacetril). Schweiz. med. Wschr. 103 (1973) 19, 711–718.

    PubMed  Google Scholar 

  11. Leake, H. C. Preliminary results with cephacetrile — a new cephalosporin. Infectious Dis. Reviews. Vol. 3 (ED.:W. J. Holloway), 10th Infect. Dis. Symp., Delaware, 1973, S. 205–217. Futura, Mount Kisco, N. Y. 1974.

    Google Scholar 

  12. Lima, M. B. C., Louro, E., Netto, A. R., Da Cunha, A. B., Polisuk, J., Albernaz, P. L. M., Bethlem, N., Santos, O. da R., De Sequeira, O. F., Aguinaga, S., Gomers, S. C. Multicentre trial with CIBA 36'278-Ba in the treatment of severe infections. Fôlha méd. 66 (1973) 827–851.

    Google Scholar 

  13. Lomar, A. V., Galvao, P. A. P., Barretto, J. G. Cephacetrile monotherapy in the treatmet of purulent meningitis. Fôlha méd. 71 (1975) 269–273.

    Google Scholar 

  14. Maurice, P. N., Riess, W., Welke, A., Amson, K. Celospor (C 36'278-Ba), ein neues Antibiotikum aus der Cephalosporinreihe: Pharmakokinetik und klinische Prüfung. Schweiz. med. Wschr. 103 (1973) 718–724.

    PubMed  Google Scholar 

  15. Meyer-Brunot, H. G., Randazzo, D., Spring, P. Theobald, W. Zur Kenntnis der Pharmakokinetik von Cephalosporinen. Cephacetril: eine Standortbestimmung. Int. Cephalosporin-Symposium, München, 5./6. 3. 76. Infection 4, Suppl. 3 (1976) 181–187.

    Google Scholar 

  16. Ponticelli, C., Zucchelli, P., Casucci., G., Cervellati, J., Dalla Rosa, G., Giro, C., Motolese, M.: Comparative multicentre trial of cephacetrile and ampicillin in the treatment of urinary infections. Abstracts, 8th Int. Congr. of Chemotherapy, Athens 1973, Vol. A.

  17. Räber, J. A.: Die Elimination der 7-Cyanacetamido-Cephalosporansäure in Patienten mit normaler und eingeschränkter nierenfunktion. Diss., S. 34, Basel 1971.

  18. Ruiz, D. E., Scholand, J., Warner, J. Single-blind comaprison of cephacetrile with cephaloridine/cephalothin. Abstr. Ann. Meet. Amer. Soc. Microbiol. 75 (1975) 2.

    Google Scholar 

  19. Sabath, L. D., Garner, C., Wilox, C., Finland, M. Effect of inoculum and of -Lactamase on the anti-staphylococcal activity of thirteen penicillins and cephalosorins. Antimicrob. Agents Chemother. 8 (1975) 344–349.

    PubMed  Google Scholar 

  20. Spring, P., Räber, J., Reber, H., Dettli, L. Die Elimination des Antibiotikums Cephacetril bei Patienten mit eingeschränkter Nierenfunktion. Schweiz. Mrd. Wschr. 103 (1973) 783–788.

    Google Scholar 

  21. Welling, P. C., Craig, W. A., Kunin, C. Predication of drug dosage in patients with renal failure using data derived from normal subjects. Clin. Pharmakol. Ther. 18 (1975) 45–52.

    Google Scholar 

  22. Williams, J. D., Andrews, J.: Sensitivity of haemophilus influenzae to antibiotics. Brit. med. J. (1974) 134–137.

  23. Wirth, K. Pharmakokinetik von Cephalosporinen. Inn. Med. 2 (1975) 41–47.

    Google Scholar 

  24. Wise, R., Reeves, D. S., Hepburn, P. R. Cephacetrile, a new cephalosporin in the treatment of urinary tract infections. Chemotherapy 20 (1974) 177–182.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinische Forschung, CH-4002, Basel

    B. R. Edselius & Ciba-Geigy AG

Authors
  1. B. R. Edselius
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ciba-Geigy AG
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Edselius, B.R., AG, CG. Einführende Daten über Cephacetril. Infection 4 (Suppl 3), S175–S180 (1976). https://doi.org/10.1007/BF01781039

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01781039

Search

Navigation